UNSPSC 51352005: Etonogestrel

This classification denotes a therapeutic progestin with the molecular formula C22H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 304GTH6RNH, chemically known as 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)- but generally known as etonogestrel, which bears US NIH Compound Identifier 40976. European Medicines Agency schedules Etonogestrel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07335MIG.

UNSPSC 51352005 Etonogestrel is a Commodity code covering procurement of the subdermal contraceptive implant, a single-rod hormonal device inserted under the skin for long-acting reversible birth control. State and local governments procure this product primarily through public health departments, Medicaid agencies, family planning clinics, and correctional health systems to support reproductive health services and women's preventive care programs. The implant is typically purchased as a finished pharmaceutical product—often under brand names such as Nexplanon—and may be bundled with insertion and removal services through related health-service codes.

The source material provided contains no recent state and local contract opportunities, solicitation records, or issuing-body activity for this code. Without posted RFP, RFQ, IFB, or ITB records, geographic concentration and representative procurement examples cannot be determined. Procurement under this code, when it occurs, likely routes through standing Medicaid contracts, cooperative pharmaceutical purchasing agreements, or health-system supply agreements rather than discrete competitive solicitations, limiting visibility in public notice channels. Business development activity under this code would benefit from direct outreach to state health departments, Medicaid managed-care organizations, and regional family planning networks rather than reliance on published solicitation activity.